Oncolytics Biotech Expects Final GOBLET Cohort 4 Results in Q4 2026
Bitget2026/10/14 13:30- Oncolytics Biotech expects final GOBLET Cohort 4 results in fourth-quarter 2026; initial Cohort 5 results are expected in first-half 2027.
- Cohort 4 tests pelareorep with atezolizumab in anal cancer; Cohort 5 evaluates pelareorep-based combinations in previously untreated metastatic pancreatic cancer.
- Every fully enrolled cohort met its prespecified efficacy success criteria; survival in Cohort 4 exceeded expectations, while Cohort 5 outcomes continue maturing.
- Cohort 5 reporting could slip as patients remain under treatment or follow-up; findings will guide pelareorep’s development with checkpoint inhibitors.
- The final PanCAN grant payment is expected this quarter, with enrollment complete; broader study infrastructure is winding down while patient follow-up continues.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Anthropic spends $3.4 billion to purchase gas-fired power equipment to supply electricity for data centers
In September, Anthropic directly acquired Caterpillar equipment orders worth 3.4 billion USD, securing 1.7 GW of gas generator units, marking the largest single purchase of power generation equipment in AI history. This move bypassed utility middlemen, capturing scarce capacity at prices set years ago with near-term delivery. It is part of Anthropic's plan to invest over 895 billion USD in computing infrastructure by 2045.

Why Nintendo Stock Is One to Watch Ahead of the Holiday Season

A wallet address sold 1.44 million TRX via SunSwap in exchange for 460,000 USDT.

Data: Whales have cumulatively withdrawn approximately 13.4 million USDT from a certain exchange.